CTXR - Citius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
4.29
-0.08 (-1.83%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.37
Open4.44
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.23 - 4.46
52 Week Range2.56 - 7.95
Volume73,354
Avg. Volume122,261
Market Cap36.136M
Beta-0.47
PE Ratio (TTM)N/A
EPS (TTM)-1.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • PR Newswire20 days ago

    Citius Pharmaceuticals to Present at Biotech Showcase™ 2018

    CRANFORD, N.J. , Jan. 4, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care ...

  • PR Newswirelast month

    Citius Announces $6 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., Dec. 18, 2017 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,280,360 shares of its common stock, at a purchase price per share of $4.6925, for gross proceeds of approximately $6 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 640,180 shares of common stock. The warrants have an exercise price of $4.63 per share, will be immediately exercisable, and will expire five and a half years from the issue date.

  • PR Newswire2 months ago

    Mino-Lok™ Phase 3 Clinical Trial Supplies Shipped to Sites

    CRANFORD, N.J., Dec. 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, has announced that clinical trial supplies of Mino-Lok (minocycline/edetate/ethanol) have been sent to the University of Chicago Medical Center, and the Henry Ford Health System in Detroit, the first 2 clinical trial sites for the Mino-Lok phase 3 pivotal trial. When fully recruited, it is planned that there will be 50 participating sites, all located in the U.S.

  • PR Newswire2 months ago

    Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational

    LOS ANGELES, Dec. 4, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it will be presenting at the 10th annual LD Micro Invitational on Wednesday, December 6th, at the Luxe Sunset Boulevard Hotel, in Los Angeles, California. Mr. Leonard Mazur, Executive Chairman of Citius, will be giving the presentation and meeting with investors.

  • PR Newswire2 months ago

    Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary

    Use of Mino-Lok™ to disinfect CVCs could avoid patient discomfort while providing an effective alternative in the treatment of Central Line Associated Bloodstream infections (CLABSIs). CRANFORD, N.J. , ...

  • PR Newswire3 months ago

    Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference

    CRANFORD, N.J. , Oct. 17, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical ...

  • PR Newswire3 months ago

    Citius Pharmaceuticals Issues Shareholder Letter

    Company Highlights Recent Nasdaq Uplisting and Additional Operational Milestones CRANFORD, N.J. , Oct. 11, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: ...

  • GuruFocus.com4 months ago

    Why Citius Pharmaceuticals Looks Undervalued

    Here's why the company should be trading higher than it is

  • PR Newswire5 months ago

    Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting

    CRANFORD, N.J., Sept. 5, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today it has received feedback from the U. S. Food and Drug Administration regarding amendments to the phase 3 study plan for Mino-Lok™, an adjunctive treatment for catheter related blood stream infection. There are currently no approved therapies to salvage infected central venous catheters ("CVCs").  Citius is currently recruiting sites for a phase 3 trial of Mino-Lok in the United States.

  • PR Newswire6 months ago

    Citius Pharmaceuticals, Inc. Announces Closing of Public Offering

    CRANFORD, N.J., Aug. 8, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (CTXR),  a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the closing of its previously announced underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125. In addition, the underwriters partially exercised the over-allotment to purchase an additional 247,272 warrants. The warrants have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance.

  • PR Newswire6 months ago

    Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market

    CRANFORD, N.J., Aug. 3, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125 per share. The warrants will have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Citius from this offering are expected to be approximately $6,800,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • PR Newswire7 months ago

    Citius Pharmaceuticals Presents At The 2017 Marcum MicroCap Conference

    NEW YORK, June 13, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire8 months ago

    Citius Pharmaceuticals Announces Reverse Stock Split

    CRANFORD, N.J., June 8, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on critical care drug products, announced today a reverse stock split of its outstanding common stock at a ratio of 1-for-15 effective at market open on Friday June 9, 2017. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 75.8 million shares to approximately 5.05 million shares.  Upon completion of the split, management will seek to secure listing on a senior exchange.  A senior exchange listing would allow us to attract a broader range of investors and to increase share liquidity. The reverse stock split will be effective with FINRA (the Financial Industry Regulatory Authority) and in the marketplace at the open of business June 9, 2017, whereupon the stock will begin trading on a split-adjusted basis.

  • PR Newswire8 months ago

    Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

    LOS ANGELES, June 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire10 months ago

    Citius Pharma Announces Addition of South America to World License

    CRANFORD, N.J., March 23, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it has recently concluded negotiations to add South America to its worldwide license for Mino-Lok™.  South America was the only territory that was not included in the original sub-license between Novel Anti-Infective Technologies, LLC, an affiliate of MD Anderson Cancer Center ("MDACC"), and Leonard-Meron Biosciences, Inc. ("LMB"), a wholly owned subsidiary of Citius Pharmaceuticals, Inc. Mr. Myron Holubiak, President and CEO stated, "The increasing importance of South American countries to the world market for pharmaceuticals and biotechnology made it compelling for us to include these countries in our license.

  • Accesswire10 months ago

    Citius Pharmaceuticals Inc. to Present at The MicroCap Conference on April 4th at 9:30 AM ET in New York City at the Essex House

    NEW YORK, NY / ACCESSWIRE / March 22, 2017 / Citius Pharmaceuticals Inc. (OTCQB: CTXR) will be presenting at this year's MicroCap Conference on April 4th in New York City. CONFERENCE OVERVIEW AND STRUCTURE ...

  • PR Newswire11 months ago

    Survey Shows Catheter Salvage in CLABSI Patients Highly Desirable

    CRANFORD, N.J., March 1, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, obtained top line data from a survey of 31 physicians clearly showing a need for catheter salvage in patients with indwelling central venous lines, especially when the catheter is a tunneled or an implanted port. There were 19 Infectious Disease experts and 12 Intensivists surveyed who all agreed that salvage would be preferable to catheter exchange fearing that catheter misplacements, blood clots, or vessel punctures can potentially occur during reinsertion. Mr. Myron Holubiak, President and CEO stated, "It is clear to us that catheter salvage is an important goal for our Mino-Lok™ development program.

  • PR Newswire11 months ago

    Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

    CRANFORD, N.J., Feb. 10, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug ...